592 related articles for article (PubMed ID: 23328549)
1. Symptom and quality of life benefit of afatinib in advanced non-small-cell lung cancer patients previously treated with erlotinib or gefitinib: results of a randomized phase IIb/III trial (LUX-Lung 1).
Hirsh V; Cadranel J; Cong XJ; Fairclough D; Finnern HW; Lorence RM; Miller VA; Palmer M; Yang JC
J Thorac Oncol; 2013 Feb; 8(2):229-37. PubMed ID: 23328549
[TBL] [Abstract][Full Text] [Related]
2. Symptom control and quality of life in LUX-Lung 3: a phase III study of afatinib or cisplatin/pemetrexed in patients with advanced lung adenocarcinoma with EGFR mutations.
Yang JC; Hirsh V; Schuler M; Yamamoto N; O'Byrne KJ; Mok TS; Zazulina V; Shahidi M; Lungershausen J; Massey D; Palmer M; Sequist LV
J Clin Oncol; 2013 Sep; 31(27):3342-50. PubMed ID: 23816967
[TBL] [Abstract][Full Text] [Related]
3. Symptom improvement in lung cancer patients treated with erlotinib: quality of life analysis of the National Cancer Institute of Canada Clinical Trials Group Study BR.21.
Bezjak A; Tu D; Seymour L; Clark G; Trajkovic A; Zukin M; Ayoub J; Lago S; de Albuquerque Ribeiro R; Gerogianni A; Cyjon A; Noble J; Laberge F; Chan RT; Fenton D; von Pawel J; Reck M; Shepherd FA;
J Clin Oncol; 2006 Aug; 24(24):3831-7. PubMed ID: 16921034
[TBL] [Abstract][Full Text] [Related]
4. Symptom and Quality of Life Improvement in LUX-Lung 8, an Open-Label Phase III Study of Second-Line Afatinib Versus Erlotinib in Patients With Advanced Squamous Cell Carcinoma of the Lung After First-Line Platinum-Based Chemotherapy.
Felip E; Hirsh V; Popat S; Cobo M; Fülöp A; Dayen C; Trigo JM; Gregg R; Waller CF; Soria JC; Goss GD; Gordon J; Wang B; Palmer M; Ehrnrooth E; Gadgeel SM
Clin Lung Cancer; 2018 Jan; 19(1):74-83.e11. PubMed ID: 28729180
[TBL] [Abstract][Full Text] [Related]
5. Does EGFR Mutation Type Influence Patient-Reported Outcomes in Patients with Advanced EGFR Mutation-Positive Non-Small-Cell Lung Cancer? Analysis of Two Large, Phase III Studies Comparing Afatinib with Chemotherapy (LUX-Lung 3 and LUX-Lung 6).
Wu YL; Hirsh V; Sequist LV; Hu CP; Feng J; Lu S; Huang Y; Schuler M; Mok T; Yamamoto N; O'Byrne K; Geater SL; Zhou C; Massey D; Märten A; Lungershausen J; Yang JC
Patient; 2018 Feb; 11(1):131-141. PubMed ID: 29178024
[TBL] [Abstract][Full Text] [Related]
6. Afatinib beyond progression in patients with non-small-cell lung cancer following chemotherapy, erlotinib/gefitinib and afatinib: phase III randomized LUX-Lung 5 trial.
Schuler M; Yang JC; Park K; Kim JH; Bennouna J; Chen YM; Chouaid C; De Marinis F; Feng JF; Grossi F; Kim DW; Liu X; Lu S; Strausz J; Vinnyk Y; Wiewrodt R; Zhou C; Wang B; Chand VK; Planchard D;
Ann Oncol; 2016 Mar; 27(3):417-23. PubMed ID: 26646759
[TBL] [Abstract][Full Text] [Related]
7. Quality of life analysis of TORCH, a randomized trial testing first-line erlotinib followed by second-line cisplatin/gemcitabine chemotherapy in advanced non-small-cell lung cancer.
Di Maio M; Leighl NB; Gallo C; Feld R; Ciardiello F; Butts C; Maione P; Gebbia V; Morgillo F; Wierzbicki R; Favaretto A; Alam Y; Cinieri S; Siena S; Bianco R; Riccardi F; Spatafora M; Ravaioli A; Felletti R; Fregoni V; Genestreti G; Rossi A; Mancuso G; Fasano M; Morabito A; Tsao MS; Signoriello S; Perrone F; Gridelli C
J Thorac Oncol; 2012 Dec; 7(12):1830-1844. PubMed ID: 23154555
[TBL] [Abstract][Full Text] [Related]
8. [Impact of erlotinib treatment on symptoms and quality of life in patients with advanced non-small-cell lung cancer].
Zhou SW; Ren SX; Yan LH; Zhang L; Zhou CC
Zhonghua Zhong Liu Za Zhi; 2008 Jun; 30(6):469-72. PubMed ID: 19024526
[TBL] [Abstract][Full Text] [Related]
9. Analysis of patient-reported outcomes from the LUME-Lung 1 trial: a randomised, double-blind, placebo-controlled, Phase III study of second-line nintedanib in patients with advanced non-small cell lung cancer.
Novello S; Kaiser R; Mellemgaard A; Douillard JY; Orlov S; Krzakowski M; von Pawel J; Gottfried M; Bondarenko I; Liao M; Barrueco J; Gaschler-Markefski B; Griebsch I; Palmer M; Reck M;
Eur J Cancer; 2015 Feb; 51(3):317-26. PubMed ID: 25534294
[TBL] [Abstract][Full Text] [Related]
10. LUX-Lung 4: a phase II trial of afatinib in patients with advanced non-small-cell lung cancer who progressed during prior treatment with erlotinib, gefitinib, or both.
Katakami N; Atagi S; Goto K; Hida T; Horai T; Inoue A; Ichinose Y; Koboyashi K; Takeda K; Kiura K; Nishio K; Seki Y; Ebisawa R; Shahidi M; Yamamoto N
J Clin Oncol; 2013 Sep; 31(27):3335-41. PubMed ID: 23816963
[TBL] [Abstract][Full Text] [Related]
11. Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial.
Miller VA; Hirsh V; Cadranel J; Chen YM; Park K; Kim SW; Zhou C; Su WC; Wang M; Sun Y; Heo DS; Crino L; Tan EH; Chao TY; Shahidi M; Cong XJ; Lorence RM; Yang JC
Lancet Oncol; 2012 May; 13(5):528-38. PubMed ID: 22452896
[TBL] [Abstract][Full Text] [Related]
12. Quality of life assessment of second-line docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy: results of a prospective, randomized phase III trial.
Dancey J; Shepherd FA; Gralla RJ; Kim YS
Lung Cancer; 2004 Feb; 43(2):183-94. PubMed ID: 14739039
[TBL] [Abstract][Full Text] [Related]
13. Quality of life in patients with advanced non-small-cell lung cancer given maintenance treatment with pemetrexed versus placebo (H3E-MC-JMEN): results from a randomised, double-blind, phase 3 study.
Belani CP; Brodowicz T; Ciuleanu TE; Krzakowski M; Yang SH; Franke F; Cucevic B; Madhavan J; Santoro A; Ramlau R; Liepa AM; Visseren-Grul C; Peterson P; John WJ; Zielinski CC
Lancet Oncol; 2012 Mar; 13(3):292-9. PubMed ID: 22336221
[TBL] [Abstract][Full Text] [Related]
14. Safety, resource use, and quality of life in paramount: a phase III study of maintenance pemetrexed versus placebo after induction pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer.
Gridelli C; de Marinis F; Pujol JL; Reck M; Ramlau R; Parente B; Pieters T; Middleton G; Corral J; Winfree K; Melemed S; Zimmermann A; John W; Beyrer J; Chouaki N; Visseren-Grul C; Paz-Ares LG
J Thorac Oncol; 2012 Nov; 7(11):1713-21. PubMed ID: 23059776
[TBL] [Abstract][Full Text] [Related]
15. Effects of erlotinib first-line maintenance therapy versus placebo on the health-related quality of life of patients with metastatic non-small-cell lung cancer.
Juhász E; Kim JH; Klingelschmitt G; Walzer S
Eur J Cancer; 2013 Apr; 49(6):1205-15. PubMed ID: 23477998
[TBL] [Abstract][Full Text] [Related]
16. Patient-reported outcomes and quality of life in PROFILE 1007: a randomized trial of crizotinib compared with chemotherapy in previously treated patients with ALK-positive advanced non-small-cell lung cancer.
Blackhall F; Kim DW; Besse B; Nokihara H; Han JY; Wilner KD; Reisman A; Iyer S; Hirsh V; Shaw AT
J Thorac Oncol; 2014 Nov; 9(11):1625-33. PubMed ID: 25436797
[TBL] [Abstract][Full Text] [Related]
17. Symptom and Quality of Life Improvement in LUX-Lung 6: An Open-Label Phase III Study of Afatinib Versus Cisplatin/Gemcitabine in Asian Patients With EGFR Mutation-Positive Advanced Non-small-cell Lung Cancer.
Geater SL; Xu CR; Zhou C; Hu CP; Feng J; Lu S; Huang Y; Li W; Hou M; Shi JH; Lee KY; Palmer M; Shi Y; Lungershausen J; Wu YL
J Thorac Oncol; 2015 Jun; 10(6):883-9. PubMed ID: 25933111
[TBL] [Abstract][Full Text] [Related]
18. Patient-reported outcomes with durvalumab after chemoradiotherapy in stage III, unresectable non-small-cell lung cancer (PACIFIC): a randomised, controlled, phase 3 study.
Hui R; Özgüroğlu M; Villegas A; Daniel D; Vicente D; Murakami S; Yokoi T; Chiappori A; Lee KH; de Wit M; Cho BC; Gray JE; Rydén A; Viviers L; Poole L; Zhang Y; Dennis PA; Antonia SJ
Lancet Oncol; 2019 Dec; 20(12):1670-1680. PubMed ID: 31601496
[TBL] [Abstract][Full Text] [Related]
19. The LUX-Lung clinical trial program of afatinib for non-small-cell lung cancer.
Metro G; Crinò L
Expert Rev Anticancer Ther; 2011 May; 11(5):673-82. PubMed ID: 21554040
[TBL] [Abstract][Full Text] [Related]
20. Health-Related Quality of Life in KEYNOTE-010: a Phase II/III Study of Pembrolizumab Versus Docetaxel in Patients With Previously Treated Advanced, Programmed Death Ligand 1-Expressing NSCLC.
Barlesi F; Garon EB; Kim DW; Felip E; Han JY; Kim JH; Ahn MJ; Fidler MJ; Gubens MA; de Castro G; Surmont V; Li Q; Deitz AC; Lubiniecki GM; Herbst RS
J Thorac Oncol; 2019 May; 14(5):793-801. PubMed ID: 30711649
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
